Search IDXX
IDEXX LABORATORIES INC /DE
Nasdaq · CIK 874716
Last close518.39
Daily change+0.64 (0.12%)
10 Years gain+358.27%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
IDXX · STANDARD
SIC 2835 · In Vitro & In Vivo Diagnostic Substances · Fiscal year end 1231
Fundamental
74.6Momentum
65.7Acceleration
79.4Confidence
91.0Annual Revenue18
Quarterly Revenue74
Annual CFO16
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth15.2 / 25
Quality20.0 / 25
Capital Efficiency17.3 / 20
Balance Sheet10.1 / 15
Shareholder Economics9.3 / 10
Forward Indicators2.6 / 5
Signals
Gross margin expansionGross margin improved by 1.2976 percentage points.
Operating leverageOperating margin improved by 3.141 percentage points.
ROIC expansionROIC improved by 12.8427 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 3.186%.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM15.99%OK
Revenue CAGR 3Y8.52%OK
Gross Margin62.99%OK
Operating Margin33.16%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC61.74%OK
Incremental Operating Margin 3Y48.72%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-3.19%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $4.30B | $2.66B | $1.36B | $1.18B | $1.06B | 61.8% | 31.6% | 24.56% | 57.27% | 81.03M |
| 2025 FY Dec 31, 2024 | $3.90B | $2.38B | $1.13B | $929.00M | $808.08M | 61.04% | 28.95% | 20.73% | 49.41% | 83.25M |
| 2025 FY Dec 31, 2023 | $3.66B | $2.19B | $1.10B | $906.51M | $772.88M | 59.82% | 29.97% | 21.11% | n/a | 83.98M |
| 2024 FY Dec 31, 2022 | $3.37B | $2.00B | $898.77M | $542.98M | $394.15M | 59.52% | 26.69% | 11.71% | n/a | 84.6M |
| 2023 FY Dec 31, 2021 | $3.22B | $1.89B | $932.03M | $755.55M | $636.00M | 58.76% | 28.99% | 19.78% | 60.24% | 86.57M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $4.57B | sum latest 4 fiscal quarters Revenue | OK | 0000874716-26-000123, 0000874716-25-000165 |
| Revenue Growth TTM | 15.99% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000874716-26-000123, 0000874716-25-000165 |
| Revenue CAGR 3Y | 8.52% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000874716-26-000038 |
| Revenue CAGR 5Y | 9.72% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000874716-26-000038 |
| Gross Profit CAGR 3Y | 9.89% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000874716-26-000038 |
| Operating Income Growth | 28.13% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0000874716-26-000123, 0000874716-25-000165 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 62.99% | Gross Profit / Revenue | OK | 0000874716-26-000123, 0000874716-25-000165 |
| Operating Margin | 33.16% | Operating Income / Revenue | OK | 0000874716-26-000123, 0000874716-25-000165 |
| ROIC | 61.74% | NOPAT / Average Invested Capital | OK | 0000874716-26-000123, 0000874716-25-000165 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000874716-26-000123 |
| Current Ratio | 1.17x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.44x | (Cash + Short-term Investments) / Total Debt | OK | 0000874716-26-000123 |
| Revenue per Diluted Share | $57.65 | Revenue / Diluted Shares | OK | 0000874716-26-000123, 0000874716-25-000165 |